Immune responses to DNA mismatch repair enzymes hMSH2 and hPMS1 in patients with pancreatic cancer, dermatomyositis and polymyositis

International Journal of Cancer

Volumn 116, Issue 6, 2005, Pages 925-933

  Okada, Takaho ^a,b   Noji, Shinobu ^a   Goto, Yasufumi ^a   Iwata, Takashi ^a   Fujita, Tomonobu ^a   Okada, Tsutomu ^a   Matsuzaki, Yuriko ^a   Kuwana, Masataka ^a   Hirakata, Michito ^a   Horii, Akira ^b   Matsuno, Seiki ^b   Sunamura, Makoto ^b   Kawakami, Yutaka ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

DNA mismatch repair enzyme; Pancreatic cancer; SEREX; Tumor antigens

Indexed keywords

CD4 ANTIGEN; COMPLEMENTARY DNA; IMMUNOGLOBULIN G ANTIBODY; PROTEIN HPMS1; PROTEIN MSH2; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIGEN DETECTION; ARTICLE; CLINICAL ARTICLE; DERMATOMYOSITIS; DIAGNOSTIC VALUE; DNA LIBRARY; FEMALE; GENE FUNCTION; GENE OVEREXPRESSION; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MALE; MISMATCH REPAIR; NUCLEOTIDE SEQUENCE; PANCREAS CANCER; PANCREAS DUCT; PNACREAS DUCT CARCINOMA; POLYMYOSITIS; PRIORITY JOURNAL;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BASE PAIR MISMATCH; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; DERMATOMYOSITIS; DNA PRIMERS; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMYOSITIS; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS; TRANSCRIPTION, GENETIC;

EID: 23944515703     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.21118     Document Type: Article

References (43)

1. Kedra B, Popiela T, Sierzega M, Precht A. Prognostic factors of long-term survival after resective procedures for pancreatic cancer. Hepatogastroenterology 2001;48:1762-6.
2. Afsari A, Zhandoug Z, Young S, Ferguson L, Silapaswan S, Mittal V. Outcome analysis of pancreaticoduodenectomy at a community hospital. Am Surg 2002;68:281-4; discussion 84-5.
3. Janes RH, Jr., Niederhuber JE, Chmiel JS, Winchester DP, Ocwieja KC, Karnell JH, Clive RE, Menck HR. National patterns of care for pancreatic cancer: results of a survey by the Commission on Cancer. Ann Surg 1996;223:261-72.
4. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
5. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivollini L, Topalian SL, Miki T, Rosenberg SA. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 1994;91:3515-9.
6. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A 1994;91:6458-62.
7. Kiniwa Y, Fujita T, Akada M, Ito K, Shofuda T, Suzuki Y, Yamamoto A, Saida T, Kawakami Y. Tumor antigens isolated from a patient with vitiligo and T-cell-infiltrated melanoma. Cancer Res 2001;61:7900-7.
8. Ueda R, Iizuka Y, Yoshida K, Kawase T, Kawakami Y, Toda M. Identification of a human glioma antigen, SOX6, recognized by patients' sera. Oncogene 2004;23:1420-7.
9. Ishikawa T, Fujita T, Suzuki Y, Okabe S, Yuasa Y, Iwai T, Kawakami Y. Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability. Cancer Res 2003;63:5564-72.
10. Ito K, Fujita T, Akada M, Kiniwa Y, Tsukamoto M, Yamamoto A, Matsuzaki Y, Matsushita M, Asano T, Nakashima J, Tachibana M, Hayakawa M, et al. Identification of bladder cancer antigens recognized by IgG antibodies of a patient with metastatic bladder cancer. Int J Cancer 2004;108:712-24.
11. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A 1995;92:11810-3.
12. Casciola-Rosen LA, Pluta AF, Plotz PH, Cox AE, Morris S, Wigley FM, Petri M, Gelber AC, Rosen A. The DNA mismatch repair enzyme PMS1 is a myositis-specific autoantigen. Arthritis Rheum 2001;44:389-96.
13. Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, Soreide O, Eriksen JA, Moller M, Baksaas I, Lothe RA, Saeterdal I, Gaudernack G. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 2001;92:441-50.
14. Gjertsen MK, Saeterdal I, Saeboe-Larssen S, Gaudernack G. HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes. J Mol Med 2003;81:43-50.
15. Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR, Goemann M, Coleman J, Grochow L, Donehower RC, Lillemoe KD, O'Reilly S, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001;19:145-56.
16. Peiper M, Goedegebuure PS, Linehan DC, Ganguly E, Douville CC, Eberlein TJ. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes. Eur J Immunol 1997;27:1115-23.
17. Tordsson J, Lavasani S, Ohlsson L, Karlstrom P, Svedberg H, Abrahmsen L, Brodin T. A3: a novel colon and pancreatic cancer reactive antibody from a primate phage library selected using intact tumour cells. Int J Cancer 2000;87:559-68.
18. Roose J, Korver W, de Boer R, Kuipers J, Hurenkamp J, Clevers H. The Sox-13 gene: structure, promoter characterization, and chromosomal localization. Genomics 1999;57:301-5.
19. Liu X, Peralta EA, Ellenhorn JD, Diamond DJ. Targeting of human p53-overexpressing tumor cells by an HLA A*0201-restricted murine T-cell receptor expressed in Jurkat T cells. Cancer Res 2000;60:693-701.
20. Scanlan MJ, Chen YT, Williamson B, Gure AO, Stockert E, Gordan JD, Tureci O, Sahin U, Pfreundschuh M, Old LJ. Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer 1998;76:652-8.
21. Scanlan MJ, Gout I, Gordon CM, Williamson B, Stockert E, Gure AO, Jager D, Chen YT, Mackay A, O'Hare MJ, Old LJ. Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression. Cancer Immun 2001;1:4.
22. Diesinger I, Bauer C, Brass N, Schaefers HJ, Comtesse N, Sybrecht G, Meese E. Toward a more complete recognition of immunoreactive antigens in squamous cell lung carcinoma. Int J Cancer 2002;102:372-8.
23. Scott HS, Antonarakis SE, Lalioti MD, Rossier C, Silver PA, Henry MF. Identification and characterization of two putative human arginine methyltransferases (HRMT1L1 and HRMT1L2). Genomics 1998;48:330-40.
24. Scorilas A, Black MH, Talieri M, Diamandis EP. Genomic organization, physical mapping, and expression analysis of the human protein arginine methyltransferase 1 gene. Biochem Biophys Res Commun 2000;278:349-59.
25. Friedrich M, Villena-Heinsen C, Meyberg R, Woll-Hermann A, Reitnauer K, Schmidt W, Tilgen W, Reichrath J. Immunohistochemical analysis of DNA "mismatch-repair" enzyme human Mut-S-Homologon-2 in ovarian carcinomas. Histochem J 1999;31:717-22.
26. Wilson TM, Ewel A, Duguid JR, Eble JN, Lescoe MK, Fishel R, Kelley MR. Differential cellular expression of the human hMSH2 repair enzyme in small and large intestine. Cancer Res 1995;55:5146-50.
27. Tureci O, Schmitt H, Fadle N, Pfreundschuh M, Sahin U. Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin's disease. J Biol Chem 1997;272:6416-22.
28. Cardillo M, Yankelevich B, Mazumder A, Lupu R. Heregulin induces increase in sensitivity of an erbB-2-overexpressing breast cancer cell type to lysis by lymphokine-activated killer cells. Cancer Immunol Immunother 1996;43:19-25.
29. Nakatsura T, Senju S, Yamada K, Jotsuka T, Ogawa M, Nishimura Y. Gene cloning of immunogenic antigens overexpressed in pancreatic cancer. Biochem Biophys Res Commun 2001;281:936-44.
30. Yamamoto H, Itoh F, Nakamura H, Fukushima H, Sasaki S, Perucho M, Imai K. Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability. Cancer Res 2001;61:3139-44.
31. Kondo E, Furukawa T, Yoshinaga K, Kijima H, Semba S, Yatsuoka T, Yokoyama T, Fukushige S, Horii A. Not hMSH2 but hMLH1 is frequently silenced by hypermethylation in endometrial cancer but rarely silenced in pancreatic cancer with microsatellite instability. Int J Oncol 2000;17:535-41.
32. Jager E, Nagata Y, Gnjatic S, Wada H, Stockert E, Karbach J, Dunbar P R, Lee SY, Jungbluth A, Jager D, Arand M, Ritter G, et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A 2000;97:4760-5.
33. Nishimura MI, Avichezer D, Custer MC, Lee CS, Chen C, Parkhurst MR, Diamond RA, Robbins PF, Schwartzentruber DJ, Rosenberg SA. MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte. Cancer Res 1999;59:6230-8.
34. Ayyoub M, Rimoldi D, Guillaume P, Romero P, Cerottini JC, Valmori D, Speiser D. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients. Cancer Res 2003;63:5601-6.
35. Ayyoub M, Hesdorffer CS, Montes M, Merlo A, Speiser D, Rimoldi D, Cerottini JC, Ritter G, Scanlan M, Old LJ, Valmori D. An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR. J Clin Invest 2004;113:1225-33.
36. Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998;187:265-70.
37. Nakatsura T, Senju S, Ito M, Nishimura Y, Itoh K. Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method. Eur J Immunol 2002;32:826-36.
38. Shichijo S, Nakao M, Imai Y, Takasu H, Kawamoto M, Niiya F, Yang D, Toh Y, Yamana H, Itoh K. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 1998;187:277-88.
39. Ralhan R, Arora S, Chattopadhyay TK, Shukla NK, Mathur M. Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India. Int J Cancer 2000;85:791-5.
40. Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 1992;326:363-7.
41. Airio A, Pukkala E, Isomaki H. Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol 1995;22:1300-3.
42. Chen YJ, Wu CY, Shen JL. Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br J Dermatol 2001;144:825-31.
43. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, Evans SR, Felson DT. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001;357:96-100.